The Anthem Biosciences IPO is creating a lot of buzz in the Indian stock market. On Day 3 (July 16, 2025), the IPO has already received strong demand across investor categories. But the big question remains should retail investors apply?
Let’s break it down in simple terms and see whether it's a good opportunity for you.
IPO Snapshot
| Detail | Information |
|---|---|
| IPO Name | Anthem Biosciences Ltd |
| IPO Type | Offer-for-Sale (OFS) |
| Price Band | ₹540 – ₹570 per share |
| Lot Size | 26 shares per lot |
| Issue Size | ₹3,395 crore |
| Open Date | July 14, 2025 |
| Close Date | July 16, 2025 |
| Allotment Date | July 17, 2025 |
| Listing Date | July 21, 2025 (Expected) |
| Exchanges | BSE and NSE |
| Registrar | KFin Technologies Ltd |
| Lead Managers | JM Financial, Citi, JP Morgan India, Nomura |
Grey Market Premium (GMP) Update
As of July
16 (Day 3), the GMP (Grey Market
Premium) for Anthem Biosciences IPO is ₹156 per share.
Implication: This means that if you get the shares at the upper end of the price band (₹570), they might list around ₹726 – a strong potential upside of 27%.
Subscription Status on Day 3 (11:30 AM)
| Investor Category | Subscription (Times) |
|---|---|
| Retail (RII) | 3.23x |
| Non-Institutional Investors (NII) | 21.13x |
| Qualified Institutional Buyers (QIB) | 4.59x |
| Overall | 7.44x |
The demand from non-institutional investors is particularly strong, indicating bullish sentiment.
What Does Anthem Biosciences Do?
Anthem Biosciences is a Contract Research, Development, and Manufacturing
Organization (CRDMO).
It offers end-to-end solutions for drug discovery, development, and manufacturing with capabilities in both New Chemical Entities (NCEs) and New Biological Entities (NBEs).
Financial Highlights
·
FY25
Revenue (Annualized): ₹1,844.55 crore
·
Profit
After Tax (PAT): ₹451 crore
·
Net Margin:
23.4%
·
EPS:
₹8.04
·
Post-Issue
P/E Ratio: 67.16 – 70.90
➡️ These numbers show strong profitability, which is rare in the pharma manufacturing space.
Should You Subscribe to Anthem Biosciences IPO?
Let’s look at both sides of the coin.
Reasons to Consider Investing
·
Strong GMP signals high demand in the unlisted
market.
·
Solid financials with 23%+ net margins.
·
Integrated operations across research,
development, and manufacturing.
·
Promoters not exiting a good sign of long-term
commitment.
·
Sector tailwinds in contract research and
speciality chemicals.
Risks to Watch
·
High P/E compared to some peers.
·
Entirely an OFS no fresh capital into the
business.
· Competitive pharma & biotech market with regulatory risks.
Final Verdict: Buy or Wait?
If you're a long-term investor or even looking for listing gains, the Anthem Biosciences IPO appears
promising. Strong fundamentals, high investor interest, and sector growth
potential make it worth considering.
Our Take: SUBSCRIBE for both short-term listing gains and long-term growth.
Key Dates to Remember
| Event | Date |
|---|---|
| IPO Closes | July 16, 2025 |
| Allotment Finalization | July 17, 2025 |
| Refunds Initiated | July 18, 2025 |
| Shares Credited to Demat | July 20, 2025 |
| Listing on BSE/NSE | July 21, 2025 (Tentative) |
Tips Before You Apply
·
Use UPI carefully to avoid payment delays.
·
Double-check your PAN and Demat details.
· Apply early on Day 3 if you haven’t already.
Frequently Asked Questions (FAQs)
Q1: Is
Anthem Biosciences IPO good for listing gains?
Yes, given the GMP of ₹156, listing gains are likely if market sentiment
remains positive.
Q2: Can
I apply through multiple accounts?
You can apply through family accounts but avoid using the same PAN.
Q3: When
will Anthem Biosciences IPO shares be listed?
Tentative listing date is July 21, 2025
on NSE and BSE.
Stay Updated
For more updates on IPOs, stock market trends, and financial news, bookmark FlipTheLoss.in your simple guide to smart investing.
0 Comments